Skip to content. | Skip to navigation


Personal tools

Christian Kollmannsberger

Peer-Reviewed Papers

 

2007

1.      Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine(R) in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs. 25(5):471-7. Epub 2007 Mar 28. (2007).

2.      Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol. 25(19):2778-84. (2007).

3.      Oechsle K, Honecker F, Kollmannsberger C, Rick O, Grunwald V, Mayer F, Hartmann JT, Bokemeyer C. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. Anticancer Drugs. 18(3):273-6. (2007).

 

2006

4.      Kollmannsberger C, Honecker F, Bokemeyer C. Treatment of germ cell tumors--update 2006. Ann Oncol. 17 Suppl 10:x31-5. (2006).

5.      Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer. 106(6):1217-26. (2006).

6.      Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 17(6):1007-13. Epub 2006 Mar 13. (2006).

7.      McArthur HL, Dalal BI, Kollmannsberger C. Intravascular hemolysis as a complication of clostridium perfringens sepsis. J Clin Oncol. 24(15):2387-8. (2006).

8.      Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. 106(5):1041-6. (2006).

 

2005

9.      Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia. J Urol. 174(6):2209-13, discussion 2213. (2005).

10.      Dalal BI, Kollmannsberger C. Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency. Br J Haematol. 129(3):291. (2005).

11.      Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke H, Schleicher J, Vanhoefer U, Jehle EC, Oechsle K, Trarbach T, Boehlke I, Kanz L, Hartmann JT, Bokemeyer C. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol. 16(8):1326-33. Epub 2005 May 26. (2005).

12.      Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann JT, Bokemeyer C. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol. 131(4):255-60. Epub 2004 Dec 31. (2005).

 

2004

13.      Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C, Gerl A, Meisner C, Ruckerl CP, Schmoll HJ, Kanz L, Oliver T. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer. 91(4):683-7. (2004).

14.      Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 22(1):108-14. (2004).

15.      Kuczyk MA, Bokemeyer C, Kollmannsberger C, Corvin S, Anastasiadis A, Machtens S, Merseburger A, Wegener G, Stenze A, Hartmann JT, Jonas U. Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World J Urol. 22(1):55-9. (2004).

16.      Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. World J Urol. 22(2):132-9. Epub 2004 Jan 21. (2004).

17.      Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker] Rofo. 176(1):76-84. (2004).

18.      Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 15(9):1377-99. (2004).

 

2003

19.      Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer. 89(1):29-35. (2003).

20.      Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schoffski P, Beyer J, Casper J, Sosada M, Schmoll HJ, Bohlke I, Meisner C, Kanz L, Bokemeyer C. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. Eur J Cancer. 39(6):775-82. (2003).

21.      Kuczyk M, Munch T, Bokemeyer C, Merseburger A, Wefer A, Kollmannsberger C, Kondoh M, Wegener G, Jonas U, Stenzl A. [Is adrenalectomy an indispensable part of nephrectomy? Results of a multivariate statistical analysis] Urologe A. 42(3):366-73. Epub 2003 Jan 15. (2003).

22.      Merseburger AS, Wegener G, Horstmann M, Oelke M, Zumbragel A, Bokemeyer C, Kollmannsberger C, Jonas U, Stenzl A, Kuczyk M. [Impact of tumor size on long-term survival of patients with organ-confined renal cell cancer] Aktuelle Urol. 34(7):469-74. (2003).

23.      Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 6(3):159-67. (2003).

24.      Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 21(22):4083-91. Epub 2003 Oct 20. (2003).

 

2002

25.      Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer. 86(4):506-11. (2002).

26.      Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs. 13(5):497-503. (2002).

27.      Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, Looijenga LH, Bokemeyer C. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer. 95(2):301-8. (2002).

28.      Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 94(9):2353-62. (2002).

29.      Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 20(8):2031-7. (2002).

30.      Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer HG, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer. 87(7):729-32. (2002).

31.      Kuczyk M, Machtens S, Bokemeyer C, Kollmannsberger C, Hartmann J, Kondoh M, Merseburger A, Jonas U. Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer. World J Urol. 20(3):183-9. Epub 2002 Jul 12. (2002).

32.      Kuczyk M, Munch T, Machtens S, Bokemeyer C, Wefer A, Hartmann J, Kollmannsberger C, Kondo M, Jonas U. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int. 89(6):517-22. (2002).

 

2001

33.      Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep. 8(6):1393-9. (2001).

34.      Kuczyk MA, Bokemeyer C, Hartmann J, Schubach J, Walter C, Machtens S, Knuchel R, Kollmannsberger C, Jonas U, Serth J. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol Rep. 8(6):1401-7. (2001).

35.      Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knuchel R, Kondo M, Jonas U, Kuczyk M. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer. 95(5):337-42. (2001).

 

2000

36.      Kollmannsberger C, Bokemeyer C. Therapy-Related Leukemia following High-Dose Chemotherapy: Compensating for the Benefit? Onkologie. 23(5):480-482. (2000).

37.      Kollmannsberger C, Gerl A, Schleucher N, Beyer J, Kuczyk M, Rick O, Casper J, Sosada M, Rie C, Kanz L, Bokemeyer C. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs. 11(7):535-9. (2000).

38.      Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schofski P, Derigs G, Ruther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol. 11(5):553-9. (2000).

39.      Kollmannsberger C, Nichols C, Meisner C, Mayer F, Kanz L, Bokemeyer C. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol. 11(9):1115-20. (2000).

40.      Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 83(4):458-62. (2000).

1999

41.      Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG). Int J Cancer. 83(6):848-51. (1999).

42.      Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol. 17(11):3450-6. (1999).

43.      Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer. 80(5-6):801-7. (1999).

44.      Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 83(6):866-9. (1999).

45.      Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, Bokemeyer C. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs. 10(8):729-33. (1999).

46.      Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, Bokemeyer C. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs. 10(5):453-6. (1999).

47.      Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer. 83(6):860-3. (1999).

48.      Pereira PL, Schick F, Einsele H, Farnsworth CT, Kollmansberger C, Mattke A, Duda SH, Claussen CD. [MR tomography of the bone marrow changes after high-dosage chemotherapy and autologous peripheral stem-cell transplantation] Rofo. 170(3):251-7. (1999).

 

1998

49.      Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 77(8):1355-62. (1998).

50.      Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L, Bokemeyer C. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs. 9(5):427-31. (1998).

51.      Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schoffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 16(10):3386-91. (1998).

52.      Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 124(3-4):207-14. (1998).

53.      Kollmannsberger C, Peters HD, Fink U. Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat Rev. 24(2):133-56. (1998).

 

1997

54.      Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs. 8(4):396-9. (1997).

 

Back to Christian Kollmannsberger

Back to Main Page